Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
Authors:
Open Access
- 26 May 2023
- journal article
- letter
- Published by Elsevier in JAAD International
- Vol. 12, 136-138
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective StudyActa Dermato-Venereologica, 2021
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*British Journal of Dermatology, 2020
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsThe Lancet, 2018
- Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapiesJournal of the American Academy of Dermatology, 2018
- Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare RegistryJournal of the American Academy of Dermatology, 2014